Uterine Cancer pp 437-441 | Cite as

Effects of Tamoxifen and Other SERMs in the Endometrium and Follow-Up of Patients

  • S. Suchetha


Hormone therapy remains an integral part of the treatment of hormone receptor-positive breast cancers. Tamoxifen, a selective estrogen receptor modulator, is the most common hormonal agent used in this scenario. Selective estrogen receptor modulators (SERMs) are competitive inhibitors of estrogen receptors which have an estrogen agonist and antagonist effect depending on target tissues. The antiestrogenic effect is by blocking the binding of estrogen to estrogen receptors.


Endometrial Cancer Breast Cancer Mortality Selective Estrogen Receptor Modulator Endometrial Thickness Endometrial Hyperplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet 2013;381:805–16.Google Scholar
  2. 2.
    Fisher B, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.CrossRefPubMedGoogle Scholar
  3. 3.
    Early Breast Cancer Trialists Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant Tamoxifen: patient-level meta-analysis of randomized trials. Lancet. 2011;378:771–84.CrossRefGoogle Scholar
  4. 4.
    Martel C, et al. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Mol Biol. 2000;74:45–56.CrossRefPubMedGoogle Scholar
  5. 5.
    Willson TM, et al. 3-[4-(1, 2-Diphenylbut-1-enyl) phenyl] acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem. 1994;37:1550–2.CrossRefPubMedGoogle Scholar
  6. 6.
    Sismond P, Biglia N, Volpi E, Giai M, de Grandis T. Tamoxifen and endometrial cancer. Ann N Y Acad Sci. 1994;734:310–21.CrossRefGoogle Scholar
  7. 7.
    Bissett D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet. 1994;344:1244.CrossRefPubMedGoogle Scholar
  8. 8.
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen treated breast cancer patients. National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37.CrossRefPubMedGoogle Scholar
  9. 9.
    Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer p. 681, 686, 689.Google Scholar
  10. 10.
    Lahti E, Blanco G, Kauppila A, Apala-Sarkkinen M, Tsinan PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993;81:660–4.PubMedGoogle Scholar
  11. 11.
    Neven P, De Muylder X, Van Belle Y, Venderick G, De Muylder E. Tamoxifen and the uterus and endometrium. Lancet. 1989;8(1):375.CrossRefGoogle Scholar
  12. 12.
    Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen treated and non treated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997;66:233–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 1994;47:827–33.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SD. Clinico-pathologic comparison of type II endometrial cancers based of tamoxifen exposure. Gynecol Oncol. 2012;127:316–20.CrossRefPubMedGoogle Scholar
  15. 15.
    Biron-Shental T, Tepper R, Fishman A, Shapira J, Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol. 2003;90:382–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Deligdisch L, Kalir N, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol. 2000;78:181–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Ashraf M, Biswas J, Majumdar S, Nayak S, Alam N, Mukherjee KK, Gupta S. Tamoxifen use in Indian women-adverse effects revisited Asian Pacific. J Cancer Prev. 2009;10:609–12.Google Scholar
  18. 18.
    Barakat RR, Gilewski TA, Almadrones L, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol. 2000;18:3459–63.PubMedGoogle Scholar
  19. 19.
    Gerber B, Krause A, Muller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol. 2000;18:3464–70.PubMedGoogle Scholar
  20. 20.
    Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994;343(8909):1318–21.Google Scholar
  21. 21.
    Cohen I, Rosen DJ, Tepper R, Cordoba M, Shapira Y, Altaras MM, et al. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med. 1993;12:275–80.PubMedGoogle Scholar
  22. 22.
    Markovitch O, Tepper R, Aviram R, Fishman A, Shapira J, Cohen I. The value of sonohysterography in the prediction of endometrial pathology in asymptomatic postmenopausal breast cancer tamoxifen treated patients. Gynecol Oncol. 2004;94:754–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  1. 1.Department of Surgical OncologyRegional Cancer CentreTrivandrumIndia

Personalised recommendations